To date, PPARγ-targeted therapy has been extensively researched for lifestyle-related diseases, such as diabetes and non-alcoholic fatty liver disease (NAFLD; Janani and Ranjitha Kumari, 2015; Cheng et al., 2019), but human applications have been partly undermined by metabolic dysregulation and carcinogenicity issues (Peters et al., 2012; Wright et al., 2014; Aghamohammadzadeh et al., 2015). This evidence concerns the gene PPARG and metabolic dysfunction-associated steatotic liver disease.